AbCellera: Losing Its Undeserved Premium

John F. Coughlin 45 Follower s Follow 5 Share Save Play ( 9min ) Comments (2) Summary AbCellera, despite massive investments in technology and talent, remains an expensive biotech with little short-term revenue avenues. Despite massive losses, management continues to issues shares to support stock-based compensation endeavors as a means to retain talent. AI premium perceived by investors is generally unfounded and is offset by massive R&D losses incurred by such technology investments. Financial backing from Canada could help extend company operating life cycle with ~$160M in remaining government funding. JHVEPhoto/iStock Editorial via Getty Images Sell Thesis Overview I wrote my last sell article about AbCellera that highlighted the Company's mounting expenses and lack of deserved premium, despite its technology-driven R&D approach to finding antibodies for a variety of autoimmune This article was written by John F. Coughlin 45 Follower s Follow Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Preview: ~298 words